Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | ABL1 | P00519 | 7/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | WEE1 | P30291 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245255 | 0.88 | FGFR1 (0.67) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5065448 | 0.85 | ABL1 (0.56) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5061792 | 0.85 | ABL1 (0.67) | SRCFGFR1EGFRABL1PDGFRB | |
| SCHEMBL2081367 | 0.84 | ABL1 (0.53) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| Hydrochloric Acid SCHEMBL4272454 | 0.83 | FGFR1 (0.46) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5763591 | 0.82 | SRC (0.77) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5065441 | 0.80 | FGFR1 (0.60) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL4839269 | 0.80 | FGFR1 (1.00) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL5762370 | 0.78 | FGFR1 (0.64) | SRCFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL27218134 | 0.77 | FGFR4 (1.00) | SRCFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | SRC 417/4885FGFR1 577/4885FGFR2 1106/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | SRC 417/4885FGFR1 577/4885FGFR2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.